Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC)

Sylvia Adams; Lori J. Goldstein; Joseph A. Sparano; Sandra Demaria; Sunil S. Badve

doi:10.4161/2162402X.2014.985930

Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC)

Sylvia Adams, Lori J. Goldstein, Joseph A. Sparano, Sandra Demaria, Sunil S. Badve

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Abstract

pon analysis of archived primary tumors of 482 patients with triple negative breast cancer (TNBC) enrolled in two randomized Phase III adjuvant chemotherapy trials, we have found that tumor infiltrating lymphocytes (TILs), as assessed and quantified by hematoxylin and eosin (H&E) staining are a robust and independent predictor of disease-free survival (DFS), distant recurrence-free interval (DRFI) and overall survival (OS).¹ Our findings provide confirmation of results observed in TNBC in a European adjuvant chemotherapy dataset and therefore elevate TILs as prognostic biomarker for operable TNBC to level I evidence.

Original language	English (US)
Pages (from-to)	1-3
Number of pages	3
Journal	OncoImmunology
Volume	4
Issue number	9
DOIs	https://doi.org/10.4161/2162402X.2014.985930
State	Published - Jan 1 2015
Externally published	Yes

Keywords

Biomarker
Breast cancer
TNBC
Tumor infiltrating lymphocytes

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4161/2162402X.2014.985930

Cite this

@article{c12f2992dd23491f8ee76246c80d5020,

title = "Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC)",

abstract = "pon analysis of archived primary tumors of 482 patients with triple negative breast cancer (TNBC) enrolled in two randomized Phase III adjuvant chemotherapy trials, we have found that tumor infiltrating lymphocytes (TILs), as assessed and quantified by hematoxylin and eosin (H&E) staining are a robust and independent predictor of disease-free survival (DFS), distant recurrence-free interval (DRFI) and overall survival (OS).1 Our findings provide confirmation of results observed in TNBC in a European adjuvant chemotherapy dataset and therefore elevate TILs as prognostic biomarker for operable TNBC to level I evidence.",

keywords = "Biomarker, Breast cancer, TNBC, Tumor infiltrating lymphocytes",

author = "Sylvia Adams and Goldstein, {Lori J.} and Sparano, {Joseph A.} and Sandra Demaria and Badve, {Sunil S.}",

note = "Publisher Copyright: {\textcopyright} 2015 Taylor & Francis Group, LLC.",

year = "2015",

month = jan,

day = "1",

doi = "10.4161/2162402X.2014.985930",

language = "English (US)",

volume = "4",

pages = "1--3",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "9",

}

TY - JOUR

T1 - Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC)

AU - Adams, Sylvia

AU - Goldstein, Lori J.

AU - Sparano, Joseph A.

AU - Demaria, Sandra

AU - Badve, Sunil S.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - pon analysis of archived primary tumors of 482 patients with triple negative breast cancer (TNBC) enrolled in two randomized Phase III adjuvant chemotherapy trials, we have found that tumor infiltrating lymphocytes (TILs), as assessed and quantified by hematoxylin and eosin (H&E) staining are a robust and independent predictor of disease-free survival (DFS), distant recurrence-free interval (DRFI) and overall survival (OS).1 Our findings provide confirmation of results observed in TNBC in a European adjuvant chemotherapy dataset and therefore elevate TILs as prognostic biomarker for operable TNBC to level I evidence.

AB - pon analysis of archived primary tumors of 482 patients with triple negative breast cancer (TNBC) enrolled in two randomized Phase III adjuvant chemotherapy trials, we have found that tumor infiltrating lymphocytes (TILs), as assessed and quantified by hematoxylin and eosin (H&E) staining are a robust and independent predictor of disease-free survival (DFS), distant recurrence-free interval (DRFI) and overall survival (OS).1 Our findings provide confirmation of results observed in TNBC in a European adjuvant chemotherapy dataset and therefore elevate TILs as prognostic biomarker for operable TNBC to level I evidence.

KW - Biomarker

KW - Breast cancer

KW - TNBC

KW - Tumor infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=84944452392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944452392&partnerID=8YFLogxK

U2 - 10.4161/2162402X.2014.985930

DO - 10.4161/2162402X.2014.985930

M3 - Article

AN - SCOPUS:84944452392

SN - 2162-4011

VL - 4

SP - 1

EP - 3

JO - OncoImmunology

JF - OncoImmunology

IS - 9

ER -

Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC)

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this